Revenue - Viatris Agreement (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Collaborative Arrangements and Co-Promote Agreement
Percentage of profit share	35.00%
Maximum potential payments receivable	$ 205,000
Collaboration revenue
Collaborative Arrangements and Co-Promote Agreement
Revenues	64,381	$ 57,208
Izencitinib | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Maximum potential payments receivable	150,000
Revefenacin Monotherapy (TD-4208)
Collaborative Arrangements and Co-Promote Agreement
Maximum potential payments receivable	160,000
Future potential combination products
Collaborative Arrangements and Co-Promote Agreement
Maximum potential payments receivable	45,000
YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Maximum potential payments receivable	160,000
YUPELRI Monotherapy | Success Based Development Regulatory And Sales Milestones
Collaborative Arrangements and Co-Promote Agreement
Maximum potential payments receivable	10,000
Development and Commercialization Agreement | Future potential combination products
Collaborative Arrangements and Co-Promote Agreement
Maximum potential payments receivable	7,500
Development and Commercialization Agreement | YUPELRI Monotherapy | Success Based Development Regulatory And Sales Milestones
Collaborative Arrangements and Co-Promote Agreement
Maximum potential payments receivable	7,500
Development and Commercialization Agreement | YUPELRI Monotherapy | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Maximum potential payments receivable	$ 37,500
Viatris
Collaborative Arrangements and Co-Promote Agreement
Percentage of profit share	65.00%
Maximum potential payments receivable	$ 45,000
Upfront payment receivable	$ 52,500
Viatris | YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Percentage of profit share	35.00%	35.00%
Maximum potential payments receivable	$ 45,000
Revenues	83,519	$ 77,337
Viatris | Collaborative Arrangement | Collaboration revenue
Collaborative Arrangements and Co-Promote Agreement
Revenues	$ 64,381	57,201
Viatris | Royalties (Non-US) | Collaboration revenue
Collaborative Arrangements and Co-Promote Agreement
Revenues		$ 7